Dana DueyAssociate Director of Research at AlivaMab Discovery Services, LLC
Dana Duey brings a combined twelve years of experience in therapeutic antibody development at both large and small biopharmaceutical companies. Dana was a founding member of the Ablexis research group responsible for creating the data package for validating the AlivaMab® Mouse. He was instrumental in the execution of the recovery and screening workflows that yielded therapeutic-quality AlivaMab antibodies.
Dana was part of the hybridoma group at Pfizer, Inc. in the metabolic disease group at Pfizer CovX and a member of Pfizer Exploratory Technologies exploring cancer stem cells. At Igenica, Inc., Dana was a founding member of the hybridoma group, establishing the hybridoma platform and assay screening methods for generating their therapeutic antibody candidates. Dana served as a scientist in the antibody discovery group at NGM Biopharmaceuticals, Inc., where he worked on diverse targets utilizing the latest tools, methods and technologies available in antibody development.
Dana received his B.S. in pharmacology from the University of California, Santa Barbara.